Browsing by Author "Wonnacott, Susan"

Now showing items 1-8 of 8

    • C3-halogenation of cytisine generates potent and efficacious nicotinic receptor agonists 
      Abin Carriquiry, Juan Andrés; Voutilainen, Merja H.; Barik, Jacques; Cassels Niven, Bruce; Iturriaga-Vásquez, Patricio; Bermúdez, Isabel; Durand, Claudia; Dajas, Federico; Wonnacott, Susan (ELSEVIER, 2006)
      Neuronal nicotinic acetylcholine receptors subserve predominantly modulatory roles in the brain, making them attractive therapeutic targets. Natural products provide key leads in the quest for nicotinic receptor subtype-selective ...
    • From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research 
      Cassels Niven, Bruce; Bermúdez, Isabel; Dajas, Federico; Abin Carriquiry, Juan Andrés; Wonnacott, Susan (ELSEVIER SCI LTD, 2005-12)
      S-Nicotine, the principal psychoactive constituent of Nicotiana tabacum, underpins addiction to tobacco smoking. Although tobacco consumption is a leading cause of death worldwide, nicotine itself is also proposed to have ...
    • In silico characterization of cytisinoids docked into an acetylcholine binding protein 
      Abin Carriquiry, Juan Andrés; Paulino Zunini, Margot; Cassels Niven, Bruce; Wonnacott, Susan; Dajas, Federico (PERGAMON-ELSEVIER SCIENCE LTD, 2010-05-06)
      Homology models of nicotinic acetylcholine receptors (nAChRs) suggest that subtype specificity is due to non-conserved residues in the complementary subunit of the ligand-binding pocket. Cytisine and its derivatives ...
    • In vivo modulation of dopaminergic nigrostriatal pathways by cytisine derivatives: Implications for Parkinson's ... 
      Abin-Carriquiry, J. Andrés; Costa, Gustavo; Urbanavicius, Jessika; Cassels Niven, Bruce; Rebolledo Fuentes, Marco; Wonnacott, Susan; Dajas, Federico (2008)
      Nicotinic acetylcholine receptor agonists are considered potential pharmacological agents for Parkinson's Disease treatment, due to their ability to improve experimental Parkinson symptomatology, reduce 3,4-dihydroxy-L-p ...
    • Increase in locomotor activity after acute administration of the nicotinic receptor agonist 3-bromocytisine in rats 
      Abin Carriquiry, Juan Andrés; Urbanavicius, Jessika; Scorza, Cecilia; Rebolledo Fuentes, Marco; Wonnacott, Susan; Cassels Niven, Bruce; Dajas, Federico (Elsevier B.V., 2010-02-23)
      Nicotinic acetylcholine receptors influence striatal dopaminergic activity and its outcome on motor behavior. For these reasons, nicotinic receptors have been considered as therapeutically relevant targets for Parkinson's ...
    • Increase in locomotor activity after acute administration of the nicotinic receptor agonist 3-bromocytisine in rats 
      Abin Carriquiry, Juan Andrés; Urbanavicius, Jessika; Scorza, Cecilia; Rebolledo Fuentes, Marco; Wonnacott, Susan; Cassels Niven, Bruce; Dajas, Federico (ELSEVIER, 2010)
      Nicotinic acetylcholine receptors influence striatal dopaminergic activity and its outcome on motor behavior. For these reasons, nicotinic receptors have been considered as therapeutically relevant targets for Parkinson's ...
    • Molecular Determinants for Competitive Inhibition of 4 2 Nicotinic Acetylcholine Receptors 
      Iturriaga-Vásquez, Patricio; Carbone, Annalisa; García Beltrán, Olimpo; Livingstone, Phil D.; Biggin, Philip C.; Cassels Niven, Bruce; Wonnacott, Susan; Zapata-Torres, Gerald; Bermúdez, Isabel (The American Society for Pharmacology and Experimental Therapeutics, 2010-06-14)
      The Erythrina alkaloids erysodine and dihydro- -erythroidine (DH E) are potent and selective competitive inhibitors of 4 2 nicotinic acetylcholine receptors (nAChRs), but little is known about the molecular determinants ...
    • Molecular Determinants for Competitive Inhibition of alpha 4 beta 2 Nicotinic Acetylcholine Receptors 
      Iturriaga-Vásquez, Patricio; Carbone, Annalisa; García Beltrán, Olimpo; Livingstone, Phil D.; Biggin, Philip C.; Cassels Niven, Bruce; Wonnacott, Susan; Zapata Torres, Gerald Amilcar; Bermúdez, Isabel (AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS, 2010-06-14)
      (DH E) are potent and selective competitive inhibitors of 4 2 nicotinic acetylcholine receptors (nAChRs), but little is known about the molecular determinants of the sensitivity of this receptor subtype to inhibition ...